Insight

Treatment-related hearing loss in medulloblastoma – TCH Pediatric Hematology Oncology Fellowship

Photo taken from TCH Pediatric Hematology Oncology Fellowship/X

Aug 2, 2024, 09:40

Treatment-related hearing loss in medulloblastoma – TCH Pediatric Hematology Oncology Fellowship

TCH Pediatric Hematology Oncology Fellowship shared on X:

“Findings in Neuro-Oncology (Oxford Academic) byand colleagues reveal for medulloblastoma that a patient’s age and the radiation dose to the cochlea inner ear are key risk factors for treatment-related hearing loss.”

The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma

Autors: Mohammad H Abu-Arja, Austin L Brown, Jack M Su, M Fatih Okcu, Holly B Lindsay, Susan L McGovern, Mary Frances McAleer, David R Grosshans, Murali M Chintagumpala, Arnold C Paulino

Treatment-

Source: TCH Pediatric Hematology Oncology Fellowship/X

Arnold C Paulino Austin L Brown cancer David R Grosshans Holly B Lindsay Jack M Su M Fatih Okcu Mary Frances McAleer medulloblastoma Mohammad Abu-Arja Murali M Chintagumpala Neurology OncoDaily Oncology Susan L McGovern TCH Pediatric Hematology Oncology Fellowship

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology